SCHEMBL9047889

SCHEMBL9047889

Clc1ncnc(Cl)c1Cc1cccc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 4/20 0.46
ADRA2B P18089 4/20 0.46
ADRA2C P18825 4/20 0.46
CTRC Q99895 1/20 0.45
ADRA1A P35348 3/20 0.44
ADRA1D P25100 2/20 0.44
ADRA1B P35368 2/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 2/20 0.43
TAAR1 Q96RJ0 2/20 0.43
LMNA P02545 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
HTR1A P08908 1/20 0.43
MAPT P10636 1/20 0.43
OPRM1 P35372 1/20 0.43
NISCH Q9Y2I1 1/20 0.43
CYP2C9 P11712 1/20 0.43
PDE4A P27815 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9046183 0.78 ALDH1A1 (0.47) ALDH1A1TAAR1LMNAPDE4APDE4B
SCHEMBL9045459 0.77 ALDH1A1 (0.47) ALDH1A1LMNAHTR1AKDM4E
SCHEMBL599659 0.74 CYP2C19 (0.62) ADRA2AADRA2BADRA2CCTRCADRA1A
SCHEMBL29490353 0.74 CYP2C19 (0.62) ADRA2AADRA2BADRA2CCTRCADRA1A
SCHEMBL2118499 0.74 CYP1A2 (0.48) ADRA2AADRA2BADRA2CCTRCADRA1A
SCHEMBL11328087 0.72 CYP2C19 (0.60) ADRA2AADRA2BADRA2CCTRCADRA1A
SCHEMBL4667060 0.72 CYP2C19 (0.60) ADRA2AADRA2BADRA2CCTRCADRA1A
Hydrogen Sulfide SCHEMBL11348128 0.72 CYP2C19 (0.60) ADRA2AADRA2BADRA2CCTRCADRA1A
SCHEMBL659517 0.72 CYP2C19 (0.60) ADRA2AADRA2BADRA2CCTRCADRA1A
SCHEMBL659516 0.72 CYP2C19 (0.60) ADRA2AADRA2BADRA2CCTRCADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0510526-B1 Use of sulfonamides as drug and new sulfonamides HOFFMANN LA ROCHE (CH) 1996-12-04 EP disclosed
US-5270313-A Treatment of circulatory disorders HOFFMANN-LA ROCHE INC. (US) 1993-12-14 US disclosed
EP-0510526-A1 Use of sulfonamides as drug and new sulfonamides F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) 1992-10-28 EP disclosed